FDA MUST "INSULATE" PREMARKET REVIEW PROCESS FROM IMPACT OF FDA REFORM LEGISLATION -- REED SMITH SHAW & McCLAY ANALYSIS; HOUSE CONFEREES APPOINTED
This article was originally published in The Gray Sheet
FDA must "insulate" its premarket review process from the potential "distractions" posed by the demands of implementing pending FDA reform legislation, an analysis of the legislation performed by the Washington, D.C. law firm of Reed Smith Shaw & McClay recommends. Noting the numerous regulations, guidances and reports mandated by the measure, the firm says "an unintended short-term effect of the FDA Modernization Act [S 830/HR 1411] may be to slow down the `nuts-and-bolts' application reviews of the agency." The analysis was co-authored by former FDA Associate Commissioner for Legislative Affairs Marc Sheineson.
You may also be interested in...
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.